An open-label extension study of rufinamide given as adjunctive therapy in patients with refractory partial seizures.

Trial Profile

An open-label extension study of rufinamide given as adjunctive therapy in patients with refractory partial seizures.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Rufinamide (Primary)
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 11 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Aug 2009 Planned initiation date (Jan 2011) added as reported by ClinicalTrials.gov.
    • 11 Aug 2009 Additional lead trial investigator Bibbiani F identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top